심혈관 치료제 : 세계 시장(-2030년)

The global market for cardiovascular drugs was valued at $183.7 billion in 2025 and is estimated to reach $228.6 billion by 2030, at a compound annual growth rate (CAGR) of 4.5% from 2025 through 2030.

The North American market for cardiovascular drugs was valued at $64.9 billion in 2025 and is estimated to reach $79.5 billion by 2030, at a CAGR of 4.1% from 2025 through 2030.

The Asia-Pacific market for cardiovascular drugs was valued at $40.4 billion in 2025 and is estimated to reach $52.5 billion by 2030, at a CAGR of 5.4% from 2025 through 2030

Report Scope

The report examines and segments the global cardiovascular drugs market by disease area, drug class, and route of administration. It also provides insights into key emerging trends and potential growth drivers. The study focuses on disease areas, including hypertension, hyperlipidemia, thrombosis, cardiac failure therapy, and other disease areas. By drug class, the market is segmented into antithrombotics, antihypertensives, lipid-lowering agents, antiarrhythmics, alpha blockers, and other drug classes. By route of administration, the market is divided into oral, intravenous, subcutaneous, and other routes of administration.

The report encompasses a comprehensive regional analysis across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA). It examines how the adoption of AI affects the cardiovascular drugs industry and broader market dynamics, including key drivers, challenges, and emerging trends. It also includes patent analysis and clinical trials of the cardiovascular drugs. The study concludes with the analysis of major companies and their offerings.

It includes global revenue ($ million) for the base year of 2024, estimated for 2025, and forecast data for 2026 through 2030.

Report Includes

• 114 data tables and 48 additional tables
• An analysis of the global markets for cardiovascular drugs
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by disease area, drug class, route of administration and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Lilly USA LLC., Bristol-Myers Squibb Co., AstraZeneca, Boehringer Ingelheim International GmbH, and Novartis AG

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Future Outlook
• Analysis of Macroeconomic Factors
• Impact of U.S. Tariffs on the Market
• Impact of the Ukraine-Russia War
• Epidemiological Trends
• Inflation and Currency Fluctuations
• Porter's Five Forces Analysis
• Potential of New Entrants: Low
• Bargaining Power of Suppliers: Moderate
• Bargaining Power of Buyers: High
• Threat of Substitutes: Moderate
• Competition in the Industry: High

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Rising Prevalence of Cardiovascular Diseases
• Improved Disease Diagnosis and Screening
• Advances in Drug Development
• Market Restraints
• Patent Expirations and Generic Competition
• Pricing and Reimbursement Issues
• Delays in Regulatory Approvals
• Market Opportunities
• Development of Novel Drug Classes
• Rising Demand for Personalized Medicine

Chapter 4 Regulatory Landscape

• Regulatory Framework
• U.S.
• Europe
• India
• Australia
• Japan

Chapter 5 Emerging Technologies and Patent Analysis

• Overview
• Emerging Technologies
• Artificial Intelligence (AI) and Machine Learning (ML)
• Nanoparticle-Mediated Drug Delivery
• Gene Therapy
• RNA-Based Therapeutics
• Intracoronary Drug Delivery
• Patent Analysis
• Key Takeaways
• Patents by Year
• Patents by Leading Jurisdiction
• Patents by Leading Inventor
• Clinical Trials Analysis

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Cardiovascular Drugs Market, by Disease Area
• Key Takeaways
• Hypertension
• Hyperlipidemia
• Thrombosis
• Cardiac Failure Therapy
• Other Disease Areas
• Global Cardiovascular Drugs Market, by Drug Class
• Key Takeaways
• Antithrombotics
• Antihypertensives
• Lipid-Lowering Agents
• Antiarrhythmics
• Alpha Blockers
• Other Drug Classes
• Global Cardiovascular Drugs Market, by Route of Administration
• Key Takeaways
• Oral
• Intravenous
• Subcutaneous
• Other Routes of Administration
• Geographic Breakdown
• Global Cardiovascular Drugs Market, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Industry Structure
• Company Share Analysis for Cardiovascular Drugs Market
• Strategic Analysis

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• GILEAD SCIENCES INC.
• HIKMA PHARMACEUTICALS PLC
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• UNITED THERAPEUTICS CORP.
• Emerging Startups/Market Disruptors